Navigation Links
OrbusNeich Announces Favorable Ruling From the European Patent Office
Date:2/12/2013

FORT LAUDERDALE, Fla., Feb. 12, 2013 /PRNewswire/ -- OrbusNeich Medical, Inc. ("OrbusNeich") announced that it received a favorable ruling from the European Patent Office ("EPO") yesterday in connection with its European Patent EP1 341 482. The '482 patent covers certain novel stents with helical structures.  It was issued by the EPO to OrbusNeich in October 2010 and does not expire until December 2021.  

In July 2011, Boston Scientific Corporation (NYSE: BSX) and Terumo Kabushiki Kaisha filed oppositions asking the EPO to revoke the '482 patent, asserting that the patent was invalid.  In response, OrbusNeich amended the claim of the '482 patent to more clearly identify the scope of its novel, helical stents.  During oral proceedings held yesterday in The Hague, the EPO upheld the claim of the '482 patent as amended.  

OrbusNeich believes that the claim of the '482 patent is infringed by current lines of Boston Scientific's stent systems.  OrbusNeich is committed to maintaining and enforcing patent protection for all of its intellectual property and innovations.  The Company is evaluating all options related to its stent patent portfolio.   

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous™ Stent, as well as other stents and balloons marketed under the names of Azule™, R stent™, Scoreflex™, Sapphire™, Sapphire II™ and Sapphire NC™. Development stage products include the COMBO Dual Therapy Stent™, the world's first dual therapy stent. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.

Global Media Contacts:
Dan Katcher / Jamie Moser
Joele Frank , Wilkinson Brimmer Katcher
(212) 355-4449


'/>"/>
SOURCE OrbusNeich Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Early Coronary Artery Healing Advantage of OrbusNeichs Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses
2. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
3. Comprehensive Care Corporation Announces New Medicare Contract with Humana Health Plan of California, Inc.
4. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Second Quarter
5. Regeneron Announces Receipt of Hart-Scott-Rodino Notice
6. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
7. Depomed Announces Appointment of Vicente J. Anido, Jr., Ph.D. to Board of Directors, and Retirement of Directors Julian N. Stern and Craig R. Smith, M.D.
8. CPhI Announces its 2nd Annual Global Pharma Regulatory Summit
9. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
10. NASP Announces Partnership with Gerry Crocker to Advance Specialty Pharmacy Industry
11. American Outcomes Management, L.P. announces the appointment of Patrick S. Smith as President and Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... 2017  Eli Lilly and Company (NYSE: ... operations to more efficiently focus resources on developing ... Global workforce reductions, including those from a U.S. ... approximately 3,500 positions. With the ... of approximately $500 million that will begin to ...
(Date:9/7/2017)... BOTHELL, Wash. , Sept. 7, 2017   BioLife ... developer, manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), announces that Mike Rice , President and ... Rodman & Renshaw 19 th ... 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
Breaking Medicine Technology:
(Date:9/21/2017)... , ... September 21, 2017 , ... With ProSlideshow Portrait ... and easy to do. Users can select from up to two layers of subject ... click of a mouse all within Final Cut Pro X. , With ...
(Date:9/21/2017)... Church, VA (PRWEB) , ... September 21, 2017 ... ... FDAnews Webinar**, Sept. 26, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... business. It’s easy to get things wrong, run afoul of The Quality System ...
(Date:9/21/2017)... ... September 21, 2017 , ... The American Addiction Treatment ... for professionals in the addiction treatment industry entitled: Special Investigations Unit (SIU) ... companies and state and federal governments are increasingly scrutinizing the addiction treatment industry ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... of a new member survey conducted by the International Society of Hair ... from 2014 to 2016 rose 60 percent, with 635,189 procedures performed in 2016. ...
(Date:9/21/2017)... San Diego, Ca (PRWEB) , ... September 21, 2017 , ... ... and affordable services to its customers, and give back to the community. For over ... on of the most successful companies serving plumbing in San Diego. They ...
Breaking Medicine News(10 mins):